Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depiquick Birch placebo-controlled phase 3 trial in birch pollen allergic rhinitis/rhinoconjunctivitis
2011-004185-14Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2011
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) comparing Depiquick Birch with Matching placebo (2 arms). Primary endpoint: Combined symptom and rescue medication score over the primary exposition time. Started Oct 2011; status: completed.
02
Drugs
Depiquick Birch
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2011-004185-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004185-14.